Abstract
Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for thrombin on human platelets, and reduces recurrent thrombotic events in stable patients with a previous myocardial infarction (MI). We wished to determine whether the efficacy and safety of antiplatelet therapy with vorapaxar was modified by concurrent thienopyridine use. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with previous atherothrombosis. This prespecified analysis included 16 897 patients who qualified with a MI in the preceding 2 weeks to 12 months and was restricted to patients without a history of stroke or transient ischemic attack given its contraindication in that population. Randomization was stratified on the basis of planned thienopyridine use. Thienopyridine was planned at randomization in 12 410 (73%). Vorapaxar significantly reduced the composite of cardiovascular death, MI, and stroke in comparison with placebo regardless of planned thienopyridine therapy (planned thienopyridine, hazard ratio, 0.80, 0.70-0.91, P<0.001; no planned thieno...Continue Reading
References
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Jan 12, 2002·BMJ : British Medical Journal·UNKNOWN Antithrombotic Trialists' Collaboration
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
May 15, 2007·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN CHARISMA Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Aug 25, 2009·American Heart Journal·David A MorrowUNKNOWN TRA 2(o)P-TIMI 50 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Aug 30, 2011·European Heart Journal·Christian W HammUNKNOWN ESC Committee for Practice Guidelines
Mar 23, 2012·Circulation·Marco ValgimigliUNKNOWN Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators
Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Aug 31, 2012·Lancet·Benjamin M SciricaUNKNOWN TRA 2°P-TIMI 50 Steering Committee Investigators
Dec 19, 2012·Circulation·Patrick T O'GaraUNKNOWN CF/AHA Task Force
Jul 20, 2014·Lancet·Jean-Philippe ColletUNKNOWN ARCTIC investigators
Sep 1, 2014·European Heart Journal·Stephan WindeckerAdam Witkowski
Sep 25, 2014·Circulation·Ezra A AmsterdamSusan J Zieman
Nov 18, 2014·The New England Journal of Medicine·Laura MauriUNKNOWN DAPT Study Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Apr 18, 2015·BMJ : British Medical Journal·Eliano Pio NavareseMarco Valgimigli
Citations
Oct 28, 2016·Molecular Pharmacology·Matthew T DuvernayHeidi E Hamm
Nov 15, 2016·Circulation·Marie D Gerhard-HermanM Eileen Walsh
Nov 15, 2016·Circulation·Marie D Gerhard-HermanM Eileen Walsh
Jul 22, 2016·Circulation·Erin A BohulaDavid A Morrow
Mar 23, 2018·Internal and Emergency Medicine·Ilaria Cavallari, Giuseppe Patti
May 20, 2016·Nature Reviews. Cardiology·Margreet R de VriesPaul H A Quax
Nov 2, 2018·Blood Advances·Moua YangRoy L Silverstein
Jan 25, 2020·Blood·Erica M SparkenbaughRafal Pawlinski
May 15, 2020·Blood·Victor R Gordeuk
Jun 2, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Jae Youn MoonDominick J Angiolillo
Jan 8, 2017·Drugs in R&D·Rebecca J GrykaSarah M Anderson
Aug 31, 2017·Journal of Managed Care & Specialty Pharmacy·Ami VyasRoss J Simpson
Jul 8, 2020·International Journal of Molecular Sciences·Erica GianazzaElena Tremoli
Dec 26, 2018·Expert Opinion on Investigational Drugs·Srikanth YandrapalliWilbert S Aronow
Jul 23, 2020·Cardiovascular Therapeutics·Rupert BauersachsMaria Huelsebeck
May 13, 2017·Vascular Medicine·UNKNOWN Writing Committee MembersDuminda N Wijeysundera
Nov 4, 2020·Circulation·William R HiattRupert Bauersachs
Mar 9, 2021·Journal of the American Heart Association·Houyong ZhuJinyu Huang